Mar 11, 2026
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct OfferingVIEW RELEASE
Mar 10, 2026
BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct OfferingVIEW RELEASE
Mar 05, 2026
BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid WithdrawalVIEW RELEASE
Stock Information
BioXcel Therapeutics, Inc.
Mar 13, 2026 04:00 PM
MARKET/SYMBOL
Nasdaq:
BTAI
PRICE
1.49
CHANGE
-0.06 (-3.87%)